Non Small Cell Lung Cancer Clinical Trials in San Antonio, Texas

28 studies are recruiting for non small cell lung cancer in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

   This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START South Texas Accelerated Research Therapeutics, San Antonio, Texas

   Locations

   17 in total

   Run by

   Aulos Bioscience, Inc.

   See if you can join NCT05267626 on ClinicalTrials.gov

2. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START San Antonio, San Antonio, Texas

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

3. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio, Texas

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

4. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

   The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

   Stage

   Not phased

   Ages

   18 and older

   Site

   The University of Texas Health Science Center at San Antonio, San Antonio, Texas

   Locations

   57 in total

   Run by

   Guardant Health, Inc.

   See if you can join NCT05059444 on ClinicalTrials.gov

5. Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

   Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab plus…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Texas Oncology - San Antonio Medical Center - Research Drive /ID# 264311, San Antonio, Texas

   Locations

   61 in total

   Run by

   AbbVie

   See if you can join NCT06236438 on ClinicalTrials.gov

6. A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

   A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site 102 - START San Antonio, San Antonio, Texas

   Locations

   6 in total

   Run by

   EpiBiologics

   See if you can join NCT07462377 on ClinicalTrials.gov

7. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   South Texas Accelerated Research Therapeutics (START), San Antonio, Texas

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

8. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

   This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesiz…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mays Cancer Center ( Site 0132), San Antonio, Texas

   Locations

   216 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06422143 on ClinicalTrials.gov

9. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   South Texas Accelerated Research Therapeutics, San Antonio, Texas

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

10. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Local Institution - 0173, San Antonio, Texas

    Locations

    186 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07100080 on ClinicalTrials.gov

11. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

    This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival ass…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Texas Oncology-San Antonio, San Antonio, Texas

    Locations

    260 in total

    Run by

    Summit Therapeutics

    See if you can join NCT05899608 on ClinicalTrials.gov

12. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

    The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    South Texas Accelerated Research Therapeutics (START), San Antonio, Texas

    Locations

    52 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06586515 on ClinicalTrials.gov

13. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

    This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UT Health San Antonio - MD Anderson Cancer Center, San Antonio, Texas

    Locations

    14 in total

    Run by

    NextCure, Inc.

    See if you can join NCT06774963 on ClinicalTrials.gov

14. A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, San Antonio, Texas

    Locations

    13 in total

    Run by

    AstraZeneca

    See if you can join NCT07115043 on ClinicalTrials.gov

15. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, San Antonio, Texas

    Locations

    42 in total

    Run by

    Inhibrx Biosciences, Inc

    See if you can join NCT04198766 on ClinicalTrials.gov

16. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

    The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Texas Oncology - San Antonio, San Antonio, Texas

    Locations

    28 in total

    Run by

    Jazz Pharmaceuticals

    See if you can join NCT06695845 on ClinicalTrials.gov

17. A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

    The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal can…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    New Experimental Therapeutics of San Antonio LLC, San Antonio, Texas

    Locations

    9 in total

    Run by

    PAQ Therapeutics, Inc.

    See if you can join NCT07300150 on ClinicalTrials.gov

18. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology /ID# 243007, San Antonio, Texas

    Locations

    48 in total

    Run by

    AbbVie

    See if you can join NCT05005403 on ClinicalTrials.gov

19. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Texas LLC - San Antonio, San Antonio, Texas

    Locations

    15 in total

    Run by

    IDEAYA Biosciences

    See if you can join NCT07503808 on ClinicalTrials.gov

20. BBO-11818 in Adult Subjects With KRAS Mutant Cancer

    A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, San Antonio, Texas

    Locations

    17 in total

    Run by

    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

    See if you can join NCT06917079 on ClinicalTrials.gov

21. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, San Antonio, Texas

    Locations

    6 in total

    Run by

    ModeX Therapeutics, An OPKO Health Company

    See if you can join NCT06239194 on ClinicalTrials.gov

22. This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

    This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, San Antonio, Texas

    Locations

    3 in total

    Run by

    Zumutor Biologics Inc.

    See if you can join NCT06451497 on ClinicalTrials.gov

23. A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

    The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants w…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas

    Locations

    26 in total

    Run by

    Frontier Medicines Corporation

    See if you can join NCT06244771 on ClinicalTrials.gov

24. A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

    This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human epidermal growth factor receptor 3 (HER3)-expressing solid tumors. The st…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, San Antonio, Texas

    Locations

    7 in total

    Run by

    Hummingbird Bioscience

    See if you can join NCT06956690 on ClinicalTrials.gov

25. A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

    The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, San Antonio, Texas

    Locations

    11 in total

    Run by

    Incendia Therapeutics

    See if you can join NCT05753722 on ClinicalTrials.gov